<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="123615">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01493284</url>
  </required_header>
  <id_info>
    <org_study_id>1105</org_study_id>
    <nct_id>NCT01493284</nct_id>
  </id_info>
  <brief_title>Assessment Of The St. Jude Medical Portico™ Transcatheter Aortic Valve Implant (TAVI) and SJM TAVI Transfemoral Delivery System</brief_title>
  <acronym>Portico TF EU</acronym>
  <official_title>Assessment Of The St. Jude Medical Portico™ Transcatheter Aortic Valve Implant (TAVI) And The SJM TAVI Transfemoral Delivery System (Portico TF EU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness of the SJM Portico
      Transcatheter Heart Valve and the SJM TAVI Transfemoral Transcatheter delivery system in
      subjects with severe symptomatic aortic stenosis (AS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data will be collected at baseline, procedure, discharge, 30 days post implant, 3 months
      post implant, 6 months post implant, and 12 months post implant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event rates</measure>
    <time_frame>30 days</time_frame>
    <description>The event rates at 30 days of the following:
Cardiovascular mortality
Myocardial Infarction (MI)
Disabling (Major) Stroke
Non-Disabling (Minor) Stroke
Acute kidney injury (AKI)
Vascular access site and access-related complications
Bleeding
Composite of periprocedural encephalopathy, all stroke, and all TIA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional improvement from baseline</measure>
    <time_frame>Baseline and 30 days</time_frame>
    <description>NYHA Functional Classification
Six Minute Walk Test
Effective Orifice Area (EOA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Device success</measure>
    <time_frame>At time of procedure</time_frame>
    <description>Successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system
Correct position of the device in the proper anatomical location
Intended performance of the prosthetic heart valve (Aortic Valve Area &gt;1.2 cm2 and mean aortic valve gradient &lt;20 mmHg or peak velocity &lt;3 m/s, without moderate or severe prosthetic valve AR)
Only one valve implanted in the proper anatomical location</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">222</enrollment>
  <condition>Symptomatic Aortic Stenosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Aortic Valve Implantation</intervention_name>
    <description>Placement of the SJM Portico aortic valve with a transfemoral delivery system</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have severe, symptomatic aortic stenosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has given written study Informed Consent for participation prior to
             procedure.

          2. Subject is ≥ 18 years of age or legal age in host country.

          3. Subject's aortic annulus diameter meets the range indicated in the Instructions for
             use as measured by echocardiogram (echo) or CT conducted within the past 90 days.

          4. Subject has senile degenerative aortic stenosis with echocardiography (echo) derived
             mean gradient &gt;40mmHg or jet velocity greater than 4.0 m/s or an initial valve area
             of &lt;1.0 cm2 (or aortic valve area index ≤ 0.6 cm2/m2). (Baseline measurement taken by
             echo within 30 days of procedure).

          5. Subject has symptomatic aortic stenosis as demonstrated by NYHA Functional
             Classification of II or greater.

          6. Subject is deemed high operable risk and suitable for TAVI per the medical opinion of
             the Subject Selection Committee (See Section 3.1 for the definition of the Subject
             Selection Committee)

          7. Subject's predicted operative mortality or serious, irreversible morbidity risk is
             &lt;50% at 30 days.

          8. In the opinion of the Subject Selection Committee and based upon angiographic
             measurements, the subject has suitable peripheral vessels and aorta to allow for
             access of the 18 French delivery system.

          9. Subject has structurally normal cardiac anatomy.

         10. Subject is willing and able to comply with all required follow-up evaluations.

        Exclusion Criteria:

          1. Subject has a history of a cerebral vascular accident (CVA) or transient ischemic
             attack (TIA) within the past 6 months (≤180 days) of the index procedure.

          2. Subject has carotid artery disease requiring intervention.

          3. Subject has evidence of a myocardial infarction (MI) within the past 6 months (≤180
             days) of the index procedure.

          4. Subject has hypertrophic cardiomyopathy.

          5. Subject has a native aortic valve that is congenitally unicuspid, bicuspid,
             quadricuspid or non-calcified as seen by echocardiography.

          6. Subject has mitral or tricuspid valvular regurgitation (&gt;grade III) or moderate to
             severe mitral stenosis.

          7. Subject has aortic root angulation &gt;70 degrees (horizontal aorta).

          8. Subject has a pre-existing prosthetic valve or prosthetic ring in any position.

          9. Subject refuses blood transfusion or surgical valve replacement.

         10. Subject has left ventricular ejection fraction (LVEF) &lt; 20%.

         11. The subject has documented, untreated coronary artery disease (CAD) requiring
             revascularization.

         12. Subject has severe basal septal hypertrophy.

         13. Subject has had a percutaneous interventional or other invasive cardiac or peripheral
             procedure ≤ 14 days of the index procedure.

         14. Subject has a history of or has active endocarditis.

         15. Subject has echocardiographic evidence of intracardiac mass, thrombus, or vegetation.

         16. Subject has hemodynamic instability (requiring inotropic support or mechanical heart
             assistance).

         17. Subject is in acute pulmonary edema or requiring intravenous diuretic therapy to
             stabilize heart failure.

         18. Subject with significant pulmonary disease.

         19. Subject has significant chronic steroid use.

         20. Subject has a known hypersensitivity or contraindication to anticoagulant or
             antiplatelet medication.

         21. Subject has renal insufficiency as evidenced by a serum creatinine &gt; 3.0 mg/dL
             (265µmol/L) or end-stage renal disease requiring chronic dialysis.

         22. Subject has morbid obesity defined as BMI ≥ 40.

         23. Subject's iliac arteries have severe calcification, tortuosity (&gt;two 90 degree
             bends), diameter &lt;6mm, or subject has had an aorto-femoral bypass.

         24. Subject has ongoing infection or sepsis.

         25. Subject has blood dyscrasias (leukopenia, acute anemia, thrombocytopenia, history of
             bleeding diathesis, or coagulopathy).

         26. Subject has a current autoimmune disease that, in the opinion of the Principal
             Investigator precludes the subject from study participation.

         27. Subject has significant aortic disease, including:

               -  aortic abdominal aneurysm (AAA) ≥ 4cm

               -  thoracic aneurysm (defined as a maximal luminal diameter of 5 cm or greater)

               -  marked tortuosity

               -  significant aortic arch atheroma or narrowing of the abdominal or thoracic aorta

               -  severe tortuosity of the thoracic aorta.

         28. Subject has a pre-existing endovascular stent graft in the supra- or infrarenal aorta
             or pre-existing stent grafts in the ileo-femoral arteries.

         29. Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within
             the past 90 days prior to the index procedure.

         30. Subject is currently participating in another investigational drug or device study.

         31. Subject requires emergency surgery for any reason.

         32. Subject has a life expectancy &lt; 12 months.

         33. Subject has other medical, social or psychological conditions that, in the opinion of
             the Subject Selection Committee, preclude the subject from study participation.

         34. Subject is suffering from dementia or admitted to a chronic care facility which would
             fundamentally complicate rehabilitation from the procedure or compliance with
             follow-up visits.

         35. Subject has a known allergy to contrast media, nitinol alloys, porcine tissue, or
             bovine tissue.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ganesh Manoharan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Victoria Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Adelaide Royal Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Bernau</name>
      <address>
        <city>Bernau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik-St. Georg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik fur Herzhirurgie Karlruhe GmbH</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glenfield Hospital</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas' Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital, Plymouth</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 14, 2016</lastchanged_date>
  <firstreceived_date>December 5, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aortic stenosis</keyword>
  <keyword>aortic valve stenosis</keyword>
  <keyword>valvular heart disease</keyword>
  <keyword>aortic valve replacement</keyword>
  <keyword>transcatheter aortic valve implantation</keyword>
  <keyword>TAVI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
